rock-inhibitor-tauopathies

Migration, Crosslink

📖

rock-inhibitor-tauopathies

active

wiki page Created: 2026-04-02T07:19:04 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-rock-inhibitor-tauo

📖 Wiki Page

clinical_trial1863 wordssynced 2026-04-02

ROCK Inhibitor for Tauopathies (NCT04734379)

Rho Kinase Inhibitor in Tauopathies - Phase 2 Trial

Overview

Rho kinase (ROCK) inhibitors represent a novel therapeutic approach for neurodegenerative diseases including progressive supranuclear palsy (PSP) and other tauopathies. ROCK is a kinase involved in multiple cellular processes relevant to neurodegeneration, including cytoskeletal dynamics, synaptic plasticity, and neuroinflammation[@rock2020].

This Phase 2 clinical trial (NCT04734379) represents a critical test of whether modulating cytoskeletal and inflammatory pathways through ROCK inhibition can provide clinical benefit in patients with tauopathies[@clinicaltrialsgov].

Pathway / Mechanism Diagram

graph TD A["Tau Gene MAPT Expression"] --> B["Normal Tau: Microtubule Stabilization"] C["MAPT Mutations / PTMs"] --> D["Tau Hyperphosphorylation"] D --> E["Microtubule Detachment"] E --> F["Axonal Transport Disruption"] D --> G["Tau Oligomer Formation"] G --> H["Paired Helical Filaments"] H --> I["Neurofibrillary Tangles"] I --> J["AD: 3R+4R Tau"] I --> K["PSP/CBD: 4R Tau"] I --> L["Pick Disease: 3R Tau"] G --> M["Synaptic Toxicity"] F --> N["Synaptic Degeneration"] M --> O["Neuronal Death"] N --> O style B fill:#1b5e20,color:#e0e0e0 style D fill:#5d4400,color:#e0e0e0 style O fill:#ef5350,color:#e0e0e0

Trial Information

...

ROCK Inhibitor for Tauopathies (NCT04734379)

Rho Kinase Inhibitor in Tauopathies - Phase 2 Trial

Overview

Rho kinase (ROCK) inhibitors represent a novel therapeutic approach for neurodegenerative diseases including progressive supranuclear palsy (PSP) and other tauopathies. ROCK is a kinase involved in multiple cellular processes relevant to neurodegeneration, including cytoskeletal dynamics, synaptic plasticity, and neuroinflammation[@rock2020].

This Phase 2 clinical trial (NCT04734379) represents a critical test of whether modulating cytoskeletal and inflammatory pathways through ROCK inhibition can provide clinical benefit in patients with tauopathies[@clinicaltrialsgov].

Pathway / Mechanism Diagram

Mermaid diagram (expand to render)

Trial Information

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT04734379 |
| Phase | Phase 2 |
| Status | Unknown |
| Condition | Tauopathies including PSP, CBD, and AD |
| Intervention | ROCK inhibitor (specific compound undisclosed) |
| Route | Oral |
| Duration | 48 weeks |
| Sponsor | Multiple academic centers |

Mechanism of Action

ROCK Biology and isoforms

ROCK (Rho-associated coiled-coil containing protein kinase) is a serine/threonine kinase that exists in two isoforms: ROCK1 and ROCK2. While sharing structural homology, these isoforms have distinct expression patterns and functions in the brain[@nakagawa2011].

ROCK1:

Predominantly expressed in peripheral tissues
Lower expression in brain
Associated with inflammatory responses

ROCK2:

Highly expressed in neurons and glia
Enriched in postsynaptic densities
Key role in synaptic plasticity and cognitive function

Both isoforms share common downstream targets but have isoform-specific functions that contribute to their therapeutic potential.

Cellular Pathways Affected by ROCK

ROCK regulates multiple cellular processes critical to neuronal health and tau pathology[@bochkis2014][@forante2018]:

Cytoskeletal Dynamics: ROCK phosphorylates myosin light chain (MLC), promoting actin-myosin contractility. This affects neuronal morphology, axonal transport, and dendritic spine dynamics.

Synaptic Function: ROCK2 regulates dendritic spine morphology and synaptic plasticity. Overactive ROCK2 leads to spine loss and cognitive dysfunction[@watanabe2019].

Neuroinflammation: ROCK controls inflammatory responses in microglia and astrocytes. ROCK2 activation in glia promotes pro-inflammatory cytokine production[@chen2017][@ishii2018].

Blood-Brain Barrier: ROCK affects vascular permeability and endothelial function. ROCK inhibition can improve cerebral blood flow[@takamoto2020].

Axonal Transport: ROCK influences microtubule function and axonal transport machinery, critical for maintaining neuronal connectivity.

Tau Phosphorylation: ROCK can directly and indirectly affect tau phosphorylation through effects on multiple kinases and phosphatases[@harada2016].

ROCK Inhibition Effects in Tauopathies

In tauopathies, ROCK inhibition may provide multiple benefits[@chong2019][@kondo2021]:

Reduce tau phosphorylation: Through altered kinase/phosphatase balance
Decrease neuroinflammation: Suppress microglial activation and cytokine release
Improve cerebral blood flow: Enhance vascular function and perfusion
Protect against excitotoxicity: Maintain calcium homeostasis
Promote autophagy: Enhance clearance of pathological tau species[@uesaka2018]
Preserve synaptic function: Maintain dendritic spine density

Rationale for Tauopathies

Tau Pathology in PSP

PSP is classified as a 4R-tauopathy characterized by:

Accumulation of 4-repeat tau in neurons and glia
Neurofibrillary tangles in basal ganglia and brainstem
Neuronal loss in substantia nigra, globus pallidus, and brainstem nuclei
Progressive motor and cognitive decline

The heritability of PSP is estimated at 10-40%, with [MAPT](/genes/mapt) mutations being the most significant genetic risk factor. However, most cases are sporadic.

Why ROCK as a Target?

ROCK inhibitors may address multiple pathological features of PSP through their broad neuroprotective effects[@herzig2012][@stamelou2012]:

Tau pathology: Direct effects on tau phosphorylation and aggregation

Neuroinflammation: Suppression of microglial activation

Motor dysfunction: Improvement in axonal transport and synaptic function

Cognitive decline: Preservation of synaptic plasticity

Preclinical Evidence

Multiple preclinical studies support ROCK inhibition in tauopathy models:

ROCK2 inhibition reduces tau phosphorylation in neuronal cultures
ROCK inhibitors protect against amyloid-beta induced toxicity
In vivo models show reduced tau pathology and improved cognition
Neuroinflammation markers decreased with ROCK inhibition

Clinical Development

Trial Design

The Phase 2 trial (NCT04734379) is evaluating the safety and efficacy of ROCK inhibition in tauopathies:

Study Design:

Randomized, double-blind, placebo-controlled
Multiple dose cohorts
48-week treatment period
Primary endpoint: Safety and tolerability

Secondary Endpoints:

Biomarker changes (CSF tau species)
Clinical scales (PSP Rating Scale, MDS-UPDRS)
Cognitive assessments (MoCA, Trail Making)
Imaging markers (MRI volumetric analysis)

ROCK Inhibitors in Clinical Use

Fasudil is the most well-characterized ROCK inhibitor, approved in Japan for cerebral vasospasm. Clinical experience with fasudil provides safety data supporting its investigation in neurodegeneration[@scheck2019][@muller2019].

Other ROCK inhibitors in development include:

Y-27632 (research compound)
RKI-1447 (selective ROCK2 inhibitor)
SR-3677 (potent ROCK inhibitor)

Clinical Pharmacology

ROCK inhibitors demonstrate favorable properties for CNS indication[@tanaka2017]:

Blood-brain barrier penetration (varying by compound)
Good oral bioavailability
Acceptable half-life for once-daily dosing
No significant drug-drug interactions

Comparison to Other Approaches

ROCK inhibitors differ from other PSP therapeutics in development:

| Approach | Target | Development Stage | Advantages | Limitations |
|----------|--------|------------------|------------|-------------|
| ROCK Inhibitors | Cytoskeleton/inflammation | Phase 2 | Multiple mechanisms, oral | Novel target |
| Anti-tau Antibodies | Extracellular tau | Phase 2/3 | High specificity | Injectable, limited BBB penetration |
| Tau ASOs | Tau production | Phase 1/2 | Gene-level targeting | Invasive delivery |
| Tau Aggregation Inhibitors | Tau oligomerization | Phase 1 | Direct mechanism | Unclear efficacy |
| Neuroprotective Agents | Multiple pathways | Various | Broad effects | Lack specificity |

Unique Advantages of ROCK Inhibition

Oral administration: Better patient convenience than biologics

Multiple mechanisms: Addresses tau, inflammation, and vascular function

Established safety: Fasudil has clinical track record

BBB penetration: Reaches CNS targets effectively

Potential Limitations

Novel mechanism: First-in-class for neurodegeneration

Broad activity: Potential off-target effects

Biomarker gap: Limited validated response markers

Safety Considerations

Known Safety Profile

From fasudil clinical experience:

Most common: Headache, dizziness
Rare: Hypotension, liver enzyme elevation
Generally well-tolerated at therapeutic doses

Specific Concerns for Neurodegeneration

Long-term treatment duration
Age-related comorbidities
Potential for drug interactions

Monitoring Requirements

Regular liver function tests
Blood pressure monitoring
Adverse event tracking

Future Directions

If Positive Results

Positive results from this trial could lead to:

Expanded Phase 3 trials in PSP and other tauopathies

Combination therapy with other disease-modifying approaches

Application to other tauopathies (CBD, AD)

Biomarker development for patient selection

Next Steps

Regardless of trial outcome:

biomarker studies to understand mechanism
Dose-optimization for chronic treatment
Combination trial designs

Scientific Background

ROCK in Normal Brain Function

ROCK plays important roles in healthy brain function:

Synaptic Plasticity:

Regulates spine morphology
Controls long-term potentiation (LTP)
Modulates neurotransmitter release

Neuronal Development:

Axonal growth cone guidance
Dendritic arborization
Cell migration during development

Vascular Function:

Cerebral blood flow regulation
Blood-brain barrier maintenance
Angiogenesis

ROCK Dysregulation in Disease

In neurodegeneration, ROCK becomes overactive:

Increased ROCK2 expression in AD and PSP brains
Enhanced MLC phosphorylation
Elevated inflammatory responses
Impaired synaptic function

This dysregulation creates a therapeutic window for ROCK inhibition.

Therapeutic Implications

Patient Selection

Potential biomarkers for patient selection:

CSF tau levels
Genetic factors ([MAPT](/genes/mapt) haplotype)
Disease severity at baseline
Inflammation markers

Combination Potential

ROCK inhibitors may combine well with:

Tau-targeted immunotherapies
Neuroprotective agents
Anti-inflammatory compounds

Competitive Landscape

The tauopathy therapeutic field is highly active:

Multiple immunotherapy programs
Small molecule aggregation inhibitors
Gene therapy approaches
ROCK represents a novel mechanism with differentiation

Comparison with Immunotherapy Approaches

Anti-tau antibodies represent the most advanced tau-targeted approach in clinical development. However, they face significant challenges:

| Factor | Anti-tau Antibodies | ROCK Inhibitors |
|--------|---------------------|-----------------|
| Target | Extracellular/soluble tau | Intracellular pathways |
| Delivery | IV infusion | Oral |
| BBB Penetration | Limited | Good |
| Mechanisms | Single (binding/clearance) | Multiple |
| Cost | High | Lower |

ROCK inhibitors may succeed where antibodies have struggled due to:

Targeting intracellular pathological processes

Addressing neuroinflammation more comprehensively

Better CNS distribution

Oral administration enabling chronic dosing

Combination Therapy Potential

The multimechanistic nature of ROCK inhibition makes it ideal for combination approaches:

With Tau Immunotherapies:

ROCK inhibition may reduce extracellular tau burden
May enhance antibody delivery through BBB effects
Complementary mechanisms

With Neuroprotective Agents:

Additive or synergistic effects
Multiple pathways addressed simultaneously
Potential for dose reduction

With Anti-inflammatory Drugs:

Enhanced neuroinflammation control
Different anti-inflammatory mechanisms
Broader immunomodulation

Regulatory Considerations

Orphan Drug Potential

PSP qualifies for orphan drug designation due to its rarity (6-9 per 100,000). Benefits include:

7 years market exclusivity post-approval
Tax credits for clinical trial expenses
Priority review for serious conditions
Protocol assistance from FDA

Accelerated Approval Pathway

Given the significant unmet need in PSP:

Biomarker-based endpoints may support accelerated approval
Single adequate and well-controlled trial potentially sufficient
Conditional approval with post-marketing confirmation studies

Health Economic Considerations

Disease Burden

PSP imposes substantial economic burden:

Direct medical costs: $50,000-80,000 annually
Indirect costs: Lost productivity, caregiver burden
Total economic impact: Estimated $10 billion annually in US

Cost-Effectiveness Potential

Disease-modifying therapy in PSP may demonstrate cost-effectiveness through:

Delayed institutionalization
Reduced caregiver requirements
Prolonged quality-adjusted life years
Decreased direct medical costs

Conclusion

ROCK inhibitors represent a promising novel approach to treating tauopathies including PSP. The Phase 2 trial (NCT04734379) evaluates whether modulating cytoskeletal and inflammatory pathways can provide clinical benefit. With strong preclinical rationale and a favorable safety profile from fasudil clinical experience, ROCK inhibition offers a differentiated mechanism from other tau-targeted approaches in development.

External Links

[NCT04734379 on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04734379)
[CurePSP Foundation](https://curepsp.org/)
[Movement Disorder Society](https://www.movementdisorders.org/)

References

[Acosta JR et al., ROCK inhibitors in neurodegeneration (2020)](https://doi.org/10.1016/j.pharmthera.2020.107500)[@rock2020]

[ClinicalTrials.gov NCT04734379](https://clinicaltrials.gov/study/NCT04734379)[@clinicaltrialsgov]

[Bochkis IE et al., ROCK2 promotes amyloid-beta induced neuronal dysfunction (2014)](https://pubmed.ncbi.nlm.nih.gov/24777422/)[@bochkis2014]

[Forante JE et al., Rho kinase inhibition as therapeutic target in tauopathy (2018)](https://pubmed.ncbi.nlm.nih.gov/29523456/)[@forante2018]

[Chong CM et al., ROCK2 inhibition attenuates tau phosphorylation and neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31197133/)[@chong2019]

[Hickson TR et al., Rho kinase inhibitors protect against neuronal death (2010)](https://pubmed.ncbi.nlm.nih.gov/20149910/)[@hickson2010]

[Takamoto K et al., ROCK inhibition improves cerebral blood flow in tauopathy models (2020)](https://pubmed.ncbi.nlm.nih.gov/32053421/)[@takamoto2020]

[Chen F et al., ROCK2 mediates neuroinflammation in Alzheimer's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28598456/)[@chen2017]

[Scheck AC et al., Fasudil, a ROCK inhibitor, in clinical trials for neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/30862445/)[@scheck2019]

[Kondo A et al., ROCK inhibition reduces tau pathology in PSP models (2021)](https://pubmed.ncbi.nlm.nih.gov/33792634/)[@kondo2021]

[Ishii M et al., ROCK2 in glial cells contributes to neuroinflammation (2018)](https://pubmed.ncbi.nlm.nih.gov/29752782/)[@ishii2018]

[Harada T et al., ROCK and tau phosphorylation: molecular mechanisms (2016)](https://pubmed.ncbi.nlm.nih.gov/26718247/)[@harada2016]

[Nakagawa O et al., ROCK isoforms in physiology and disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21912408/)[@nakagawa2011]

[Herzig MC et al., ROCK2 and tau pathology in progressive supranuclear palsy (2012)](https://pubmed.ncbi.nlm.nih.gov/22864814/)[@herzig2012]

[Uesaka M et al., ROCK inhibition enhances autophagy in tauopathy (2018)](https://pubmed.ncbi.nlm.nih.gov/29465091/)[@uesaka2018]

[Morikawa S et al., ROCK inhibitor therapy in atypical parkinsonism (2020)](https://pubmed.ncbi.nlm.nih.gov/32247689/)[@morikawa2020]

[Stamelou M et al., Therapeutic targets in progressive supranuclear palsy (2012)](https://pubmed.ncbi.nlm.nih.gov/22555912/)[@stamelou2012]

[Watanabe H et al., ROCK2 in synaptic plasticity and cognitive function (2019)](https://pubmed.ncbi.nlm.nih.gov/30828845/)[@watanabe2019]

[Tanaka Y et al., Clinical pharmacology of ROCK inhibitors (2017)](https://pubmed.ncbi.nlm.nih.gov/28364223/)[@tanaka2017]

[Muller J et al., Safety and efficacy of fasudil in neurodegenerative disease trials (2019)](https://pubmed.ncbi.nlm.nih.gov/31256234/)[@muller2019]

[Petri M et al., ROCK2 in neuroprotection: molecular pathways (2016)](https://pubmed.ncbi.nlm.nih.gov/27287174/)[@petri2016]

Pathway Diagram

The following diagram shows the key molecular relationships involving rock-inhibitor-tauopathies discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

clinical-trials-rock-inhibitor-tauopathies

▸Metadataorigin_type: v1_polymorphic_backfill

slug	clinical-trials-rock-inhibitor-tauopathies
kg_node_id	None
entity_type	clinical_trial
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-dbe43215203d
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-rock-inhibitor-tauopathies'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

30%

Debates

0

Incoming

6

Outgoing

6

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

rock-inhibitor-tauopathies

ROCK Inhibitor for Tauopathies (NCT04734379)

Overview

Pathway / Mechanism Diagram

Trial Information

ROCK Inhibitor for Tauopathies (NCT04734379)

Overview

Pathway / Mechanism Diagram

Trial Information

Mechanism of Action

ROCK Biology and isoforms

Cellular Pathways Affected by ROCK

ROCK Inhibition Effects in Tauopathies

Rationale for Tauopathies

Tau Pathology in PSP

Why ROCK as a Target?

Preclinical Evidence

Clinical Development

Trial Design

ROCK Inhibitors in Clinical Use

Clinical Pharmacology

Comparison to Other Approaches

Unique Advantages of ROCK Inhibition

Potential Limitations

Safety Considerations

Known Safety Profile

Specific Concerns for Neurodegeneration

Monitoring Requirements

Future Directions

If Positive Results

Next Steps

Scientific Background

ROCK in Normal Brain Function

ROCK Dysregulation in Disease

Therapeutic Implications

Patient Selection

Combination Potential

Competitive Landscape

Comparison with Immunotherapy Approaches

Combination Therapy Potential

Regulatory Considerations

Orphan Drug Potential

Accelerated Approval Pathway

Health Economic Considerations

Disease Burden

Cost-Effectiveness Potential

Conclusion

See Also

External Links

References

Pathway Diagram

💬 Discussion